Exelixis Inc.

Exelixis Inc. is a biotechnology company specializing in the discovery, development, and commercialization of innovative cancer therapies. With a focus on oncology, the company leverages advanced genomics and a science-driven approach to create both small molecule drugs and biotherapeutics aimed at improving outcomes for patients with serious malignancies. Key products include Cabometyx and Cometriq, which are approved treatments for advanced forms of renal cell carcinoma, hepatocellular carcinoma, and other cancers. Exelixis maintains an expanding pipeline featuring candidates targeting advanced or metastatic solid tumors, reflecting its commitment to addressing unmet needs in cancer treatment. Strategic collaborations with major biopharmaceutical partners further enhance the company's research, development, and global reach. Over nearly three decades, Exelixis has evolved into a multi-platform cancer company, consistently contributing to advancements in oncology care and offering hope to patients through novel and effective therapeutic options.